Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

EC approves label expansion for Bial-Portela's epilepsy drug Zebinix

Alex Himes
July 28, 2017 6:12 AM UTC

In May, the European Commission approved a label expansion for Zebinix eslicarbazepine acetate (Aptiom - U.S.) (BIA 2-093, SEP-0002093) from Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) to include its use as monotherapy to treat partial-onset seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bial-portela & Ca. S.A.

Eisai Co. Ltd.